Ambrilia Terminates Phase III Study 303
Ambrilia has reported the termination of the phase III clinical Study 303. The move is in line with the company’s ongoing measures to effectively reduce costs. Reportedly, study
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).